<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457520</url>
  </required_header>
  <id_info>
    <org_study_id>ABS157LT</org_study_id>
    <nct_id>NCT02457520</nct_id>
  </id_info>
  <brief_title>ABSORICA in Patients With Severe Recalcitrant Nodular Acne</brief_title>
  <official_title>An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an uncontrolled, open-label study being conducted in approximately 200 healthy males,&#xD;
      non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.&#xD;
&#xD;
      ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by&#xD;
      1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or&#xD;
      abstinence are included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to collect efficacy, safety, and quality of life (QOL) data from&#xD;
      subjects who receive Absorica® without food. The study will investigate the treatment&#xD;
      efficacy, frequency of relapse once the treatment has been discontinued, quality of life&#xD;
      during the active treatment and during a 2-year post treatment period and the overall safety&#xD;
      of treatment with Absorica®.&#xD;
&#xD;
      This is a single-arm, open-label study consisting of 2 phases: a 20-week (5-month) open-label&#xD;
      Active Treatment Period (ATP) and a 104-week (2-year) post treatment period (PTP). The total&#xD;
      study duration is to be 124 weeks, excluding a screening period. During the ATP, after week 2&#xD;
      visit, visits will be scheduled at 4-week intervals for a total of 8 visits (1 screening&#xD;
      visit, 1 baseline visit, and 6 on-study visits). During the PTP, the first visit will be 4&#xD;
      weeks after End of Treatment (EOT), the second visit will be 12 weeks after EOT, and&#xD;
      subsequent visits will be scheduled at 26-week (± 2 weeks) intervals for a total of 6 visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20</measure>
    <time_frame>Week 20</time_frame>
    <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint, Post-treatment Period: Subjects Requiring Retreatment During the Post-treatment Period and Time to Retreatment</measure>
    <time_frame>20 weeks</time_frame>
    <description>subjects who were at least 75% compliant with their assigned treatment, had no major protocol violations, had a Week 20 count of total nodular lesions, and did not use any disallowed medications during the 20 weeks of treatment. (Retreated with Oral Isotretinoin Per Protocol Population).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Active Treatment Period- Change From Baseline in Lesion Counts at Week 20</measure>
    <time_frame>Baseline and at week 20</time_frame>
    <description>Change from baseline in the lesion count (nodules and inflammatory lesions) at the end of the ATP. (Per Protocol Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Treatment Period-Change From Baseline in Acne-Specific Quality of Life Total Score at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Baseline, at week 4, week 8, week 12, and week16</time_frame>
    <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Treatment Period- Investigator's Global Assessment at Week 20</measure>
    <time_frame>week 20</time_frame>
    <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Treatment Period- Change From Baseline in Acne-Specific Quality of Life Domain Scores by Domain at Weeks 4, 8, 12, and 16</measure>
    <time_frame>20 weeks</time_frame>
    <description>Acne-Specific Quality of Life, by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Treatment Period- Change From Baseline in Nodule Count at Week 20</measure>
    <time_frame>Baseline, and at week20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Proportion of Subjects Requiring Treatment With Anti-Acne Medication and Time to Retreatment</measure>
    <time_frame>104 weeks</time_frame>
    <description>Retreated with Prescription Anti-Acne Medication, n/Na (%); Over-the-Counter Anti-Acne Medication and Prescription or Over-the-Counter Anti-Acne Medication- Per Protocol Population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Oral Isotretinoin</measure>
    <time_frame>104 weeks</time_frame>
    <description>change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Severity of Acne by Investigator's Global Assessment at Time of Retreatment With Oral Isotretinoin</measure>
    <time_frame>104 weeks</time_frame>
    <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Prescription Other Than Oral Isotretinoin</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Over-the-Counter Medication</measure>
    <time_frame>20 weeks</time_frame>
    <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period-Severity of Acne by Lesion Count at Each Visit During the Post-treatment Period</measure>
    <time_frame>week 124</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Treatment Period- Severity of Acne by Nodule Count at Each Visit During the Post-treatment Period</measure>
    <time_frame>week 124</time_frame>
    <description>Change from Baseline-Week 124</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Acne by Investigator's Global Assessment Score at Each Visit During the Post-treatment Period</measure>
    <time_frame>week 124</time_frame>
    <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Over-the-Counter Medications</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Treatment Period-Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Prescription Other Than Oral Isotretinoin</measure>
    <time_frame>20 weeks</time_frame>
    <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post Treatment Period- Acne-Specific Quality of Life by Total Scores at the End of the Post-treatment Period</measure>
    <time_frame>Visit 14/Week 124</time_frame>
    <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-treatment Period- Acne-Specific Quality of Life by Domain Scores at the End of the Post-treatment Period</measure>
    <time_frame>Visit 14/Week 124</time_frame>
    <description>Acne-Specific Quality of Life, total and by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Single treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
    <arm_group_label>Single treatment arm</arm_group_label>
    <other_name>ABSORICA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria Subjects must meet the following mandatory inclusion criteria at&#xD;
        the time of screening to be eligible to enter the study and must agree to conform to the&#xD;
        requirements of the study and the iPLEDGE program.&#xD;
&#xD;
          -  Written informed consent, including mandatory photographic consent, on a&#xD;
             gender-specific informed consent form (ICF) &amp; Health Insurance Portability and&#xD;
             Accountability Act (HIPAA) authorization prior to the performance of any study-related&#xD;
             procedures.&#xD;
&#xD;
          -  Pregnant females and females who are not to become pregnant during the ATP phase of&#xD;
             the trial and for 30 days after receiving their last dose of study drug.&#xD;
&#xD;
          -  Female subjects of childbearing potential ready to use 2 forms of effective&#xD;
             contraception simultaneously for 1 month before starting Absorica® (isotretinoin),&#xD;
             while taking Absorica® &amp; for 1 month after Absorica® has been stopped.&#xD;
&#xD;
          -  Male and female subjects of non-childbearing potential&#xD;
&#xD;
        Specific Inclusion Criteria:&#xD;
&#xD;
          -  Severe recalcitrant nodular acne.&#xD;
&#xD;
          -  Five or more nodule lesions on the face.&#xD;
&#xD;
          -  Treatment-naïve subjects.&#xD;
&#xD;
          -  Age between 12 and 45 years.&#xD;
&#xD;
          -  Weight between 40 and 110 kg.&#xD;
&#xD;
          -  Female subjects of childbearing potential only: Negative results from serum pregnancy&#xD;
             tests with a sensitivity of at least 25 milli-international unit/mL.&#xD;
&#xD;
          -  Good general health as determined by the investigator based on the subject's medical&#xD;
             history, physical examination, vital signs measurements, and laboratory test results.&#xD;
&#xD;
          -  Subjects who present with stable &amp; controlled diabetes mellitus (Types I and II).&#xD;
&#xD;
          -  Subjects with previously diagnosed polycystic ovarian syndrome (PCOS) can be included&#xD;
             in the study if in the opinion of the investigator they do not have any other&#xD;
             clinically significant abnormality (eg, metabolic syndrome or elevated lipids&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          -  Presence of any clinically significant physical examination finding, vital signs&#xD;
             measurement, or abnormal laboratory value;&#xD;
&#xD;
          -  Presence of a beard or other facial hair that could interfere with the study&#xD;
             assessments;&#xD;
&#xD;
          -  Participated in another clinical trial or received an investigational product within 3&#xD;
             months prior to screening;&#xD;
&#xD;
          -  History of excessive or suspected abuse of alcohol (based on the clinical judgment of&#xD;
             the investigator), recreational drugs, and/or drugs of abuse, e.g., club drugs,&#xD;
             cocaine, ecstasy/ methylenedioxymethamphetamine, heroin, inhalants, marijuana,&#xD;
             methamphetamine, phencyclidine, prescription medications, anabolic steroids, etc.&#xD;
&#xD;
          -  Use of prohibited or restricted prior or concomitant medications. Female Specific&#xD;
             Exclusion Criteria&#xD;
&#xD;
          -  Are pregnant;&#xD;
&#xD;
          -  Are at a high risk for becoming pregnant or likely to become pregnant during&#xD;
             treatment;&#xD;
&#xD;
          -  Are breast-feeding or considering breast-feeding during the course of the study;&#xD;
&#xD;
          -  Have a known history of PCOS with another clinically significant abnormality (eg,&#xD;
             metabolic syndrome or elevated lipids);&#xD;
&#xD;
          -  Are unable or unwilling to maintain compliance with birth control measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish Anvekar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ranbaxy Laboratories Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 16, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 19, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02457520/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Treatment Arm</title>
          <description>Absorica capsules 0.5 mg/kg/day for 4 weeks, followed by 1.0 mg/kg/day for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Active Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201">All subjects received treatment according to the same regimen.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other: Retreatment Required</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Single Treatment Arm</title>
          <description>Absorica capsules 0.5 mg/kg/day for 4 weeks, followed by 1.0 mg/kg/day for 16 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only Hispanic or Latino and Non-Hispanic or Latino were included in the study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20</title>
        <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
        <time_frame>Week 20</time_frame>
        <population>This endpoint was analyzed in the per-protocol population and the number of participants analyzed in the per-protocol population set was 166.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20</title>
          <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
          <population>This endpoint was analyzed in the per-protocol population and the number of participants analyzed in the per-protocol population set was 166.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint, Post-treatment Period: Subjects Requiring Retreatment During the Post-treatment Period and Time to Retreatment</title>
        <description>subjects who were at least 75% compliant with their assigned treatment, had no major protocol violations, had a Week 20 count of total nodular lesions, and did not use any disallowed medications during the 20 weeks of treatment. (Retreated with Oral Isotretinoin Per Protocol Population).</description>
        <time_frame>20 weeks</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint, Post-treatment Period: Subjects Requiring Retreatment During the Post-treatment Period and Time to Retreatment</title>
          <description>subjects who were at least 75% compliant with their assigned treatment, had no major protocol violations, had a Week 20 count of total nodular lesions, and did not use any disallowed medications during the 20 weeks of treatment. (Retreated with Oral Isotretinoin Per Protocol Population).</description>
          <population>Per Protocol Population</population>
          <units>number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Treatment Period- Change From Baseline in Lesion Counts at Week 20</title>
        <description>Change from baseline in the lesion count (nodules and inflammatory lesions) at the end of the ATP. (Per Protocol Population)</description>
        <time_frame>Baseline and at week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period- Change From Baseline in Lesion Counts at Week 20</title>
          <description>Change from baseline in the lesion count (nodules and inflammatory lesions) at the end of the ATP. (Per Protocol Population)</description>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-89.14" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Treatment Period-Change From Baseline in Acne-Specific Quality of Life Total Score at Weeks 4, 8, 12, and 16</title>
        <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
        <time_frame>Baseline, at week 4, week 8, week 12, and week16</time_frame>
        <population>PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Week 16</title>
            <description>Visit 7/Week 16&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm-Week 12</title>
            <description>Visit 6/Week 12&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm-Week 8</title>
            <description>Visit 5/Week 8&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>Single Treatment Arm-Week 4</title>
            <description>Visit 4/Week 4&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period-Change From Baseline in Acne-Specific Quality of Life Total Score at Weeks 4, 8, 12, and 16</title>
          <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
          <population>PP population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="28.1"/>
                    <measurement group_id="O2" value="26.3" spread="24.6"/>
                    <measurement group_id="O3" value="17.8" spread="22.4"/>
                    <measurement group_id="O4" value="14.5" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Treatment Period- Investigator's Global Assessment at Week 20</title>
        <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
        <time_frame>week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period- Investigator's Global Assessment at Week 20</title>
          <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Treatment Period- Change From Baseline in Acne-Specific Quality of Life Domain Scores by Domain at Weeks 4, 8, 12, and 16</title>
        <description>Acne-Specific Quality of Life, by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
        <time_frame>20 weeks</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Self Perception</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm-Role-Emotional</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm-Role-Social</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>Single Treatment Arm-Acne Symptoms</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period- Change From Baseline in Acne-Specific Quality of Life Domain Scores by Domain at Weeks 4, 8, 12, and 16</title>
          <description>Acne-Specific Quality of Life, by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
          <population>per protocol population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="166"/>
                <count group_id="O4" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 8/Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="166"/>
                    <count group_id="O4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="8.9"/>
                    <measurement group_id="O2" value="10.5" spread="8.7"/>
                    <measurement group_id="O3" value="6.5" spread="7.1"/>
                    <measurement group_id="O4" value="11.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7/Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="159"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="159"/>
                    <count group_id="O4" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="8.8"/>
                    <measurement group_id="O2" value="8.7" spread="8.7"/>
                    <measurement group_id="O3" value="5.4" spread="7.1"/>
                    <measurement group_id="O4" value="9.7" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6/Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="163"/>
                    <count group_id="O4" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.9"/>
                    <measurement group_id="O2" value="6.9" spread="7.8"/>
                    <measurement group_id="O3" value="4.3" spread="6.0"/>
                    <measurement group_id="O4" value="8.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5/Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="162"/>
                    <count group_id="O4" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="7.1"/>
                    <measurement group_id="O2" value="4.5" spread="7.1"/>
                    <measurement group_id="O3" value="2.6" spread="5.3"/>
                    <measurement group_id="O4" value="6.1" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4/Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="149"/>
                    <count group_id="O4" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="6.3"/>
                    <measurement group_id="O2" value="4.0" spread="6.5"/>
                    <measurement group_id="O3" value="2.1" spread="5.2"/>
                    <measurement group_id="O4" value="4.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Treatment Period- Change From Baseline in Nodule Count at Week 20</title>
        <time_frame>Baseline, and at week20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Active Treatment Period- Change From Baseline in Nodule Count at Week 20</title>
          <units>percentage change in nodule count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.18" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Proportion of Subjects Requiring Treatment With Anti-Acne Medication and Time to Retreatment</title>
        <description>Retreated with Prescription Anti-Acne Medication, n/Na (%); Over-the-Counter Anti-Acne Medication and Prescription or Over-the-Counter Anti-Acne Medication- Per Protocol Population.</description>
        <time_frame>104 weeks</time_frame>
        <population>PP population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Retreat With Prescription Anti-acne Medic</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm - Retreat With Over-the-counter Anti-acne</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm- Retreat With Prescription or Over-the-co</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Proportion of Subjects Requiring Treatment With Anti-Acne Medication and Time to Retreatment</title>
          <description>Retreated with Prescription Anti-Acne Medication, n/Na (%); Over-the-Counter Anti-Acne Medication and Prescription or Over-the-Counter Anti-Acne Medication- Per Protocol Population.</description>
          <population>PP population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Oral Isotretinoin</title>
        <description>change from Baseline</description>
        <time_frame>104 weeks</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm- Total</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm -Non-inflammatory</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm-Inflammatory</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Oral Isotretinoin</title>
          <description>change from Baseline</description>
          <population>Per Protocol Population</population>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.81" spread="31.15"/>
                    <measurement group_id="O2" value="-1.41" spread="95.81"/>
                    <measurement group_id="O3" value="-31.53" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Severity of Acne by Investigator's Global Assessment at Time of Retreatment With Oral Isotretinoin</title>
        <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
        <time_frame>104 weeks</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Severity of Acne by Investigator's Global Assessment at Time of Retreatment With Oral Isotretinoin</title>
          <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
          <population>Per Protocol Population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Prescription Other Than Oral Isotretinoin</title>
        <description>Change from baseline</description>
        <time_frame>104 weeks</time_frame>
        <population>(Per Protocol Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Inflammatory</title>
            <description>Change from baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm -Non-inflammatory</title>
            <description>Change from baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm- Total</title>
            <description>Change from baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Prescription Other Than Oral Isotretinoin</title>
          <description>Change from baseline</description>
          <population>(Per Protocol Population)</population>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.16" spread="25.93"/>
                    <measurement group_id="O2" value="-72.90" spread="30.52"/>
                    <measurement group_id="O3" value="-69.83" spread="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Over-the-Counter Medication</title>
        <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
        <time_frame>20 weeks</time_frame>
        <population>Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Over-the-Counter Medication</title>
          <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
          <population>Per Protocol population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period-Severity of Acne by Lesion Count at Each Visit During the Post-treatment Period</title>
        <time_frame>week 124</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Inflammatory</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm -Non-inflammatory</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm- Total</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period-Severity of Acne by Lesion Count at Each Visit During the Post-treatment Period</title>
          <population>PP Population</population>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.85" spread="18.89"/>
                    <measurement group_id="O2" value="-80.45" spread="37.10"/>
                    <measurement group_id="O3" value="-85.35" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Treatment Period- Severity of Acne by Nodule Count at Each Visit During the Post-treatment Period</title>
        <description>Change from Baseline-Week 124</description>
        <time_frame>week 124</time_frame>
        <population>Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post Treatment Period- Severity of Acne by Nodule Count at Each Visit During the Post-treatment Period</title>
          <description>Change from Baseline-Week 124</description>
          <population>Per Protocol population</population>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-99.03" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Acne by Investigator's Global Assessment Score at Each Visit During the Post-treatment Period</title>
        <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
        <time_frame>week 124</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acne by Investigator's Global Assessment Score at Each Visit During the Post-treatment Period</title>
          <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
          <population>per protocol population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Over-the-Counter Medications</title>
        <description>Change from Baseline</description>
        <time_frame>20 weeks</time_frame>
        <population>(Per Protocol Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Inflammatory</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm -Non-inflammatory</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm- Total</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Severity of Acne by Lesion Count at Time of Retreatment With Over-the-Counter Medications</title>
          <description>Change from Baseline</description>
          <population>(Per Protocol Population)</population>
          <units>percentage change in lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.61" spread="17.26"/>
                    <measurement group_id="O2" value="-63.70" spread="38.38"/>
                    <measurement group_id="O3" value="-67.04" spread="21.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Treatment Period-Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Prescription Other Than Oral Isotretinoin</title>
        <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
        <time_frame>20 weeks</time_frame>
        <population>(Per Protocol Population)</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post Treatment Period-Severity of Acne by Investigator's Global Assessment Score at Time of Retreatment With Prescription Other Than Oral Isotretinoin</title>
          <description>Investigator's Global Assessment score:&#xD;
0 = Clear&#xD;
= Almost Clear&#xD;
= Mild&#xD;
= Moderate&#xD;
= Severe&#xD;
= Very Severe</description>
          <population>(Per Protocol Population)</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post Treatment Period- Acne-Specific Quality of Life by Total Scores at the End of the Post-treatment Period</title>
        <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
        <time_frame>Visit 14/Week 124</time_frame>
        <population>PP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm- Visit 14/ Week 124</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Post Treatment Period- Acne-Specific Quality of Life by Total Scores at the End of the Post-treatment Period</title>
          <description>There are 4 domains: self-perception (22 questions), role-social (50 questions), role-emotional (33 questions), and acne symptoms (85 questions) in the acne-QOL questionnaires.&#xD;
Calculation of the domain scores was accomplished by summing all item responses within each domain.&#xD;
Self-perception: The range of possible scores is 0 to 30 points. Role-social: The range of possible scores is 0 to 24 points. Role emotional: The domain scores range from 0 to 30 points. Acne symptoms: The domain scores range from 0 to 30 points.</description>
          <population>PP Population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-treatment Period- Acne-Specific Quality of Life by Domain Scores at the End of the Post-treatment Period</title>
        <description>Acne-Specific Quality of Life, total and by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
        <time_frame>Visit 14/Week 124</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment Arm-Self Perception</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Single Treatment Arm-Role-Emotional</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Single Treatment Arm-Role-Social</title>
            <description>Change from Baseline&#xD;
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Isotretinoin: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>Single Treatment Arm-Acne Symptoms</title>
            <description>Change from Baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Period- Acne-Specific Quality of Life by Domain Scores at the End of the Post-treatment Period</title>
          <description>Acne-Specific Quality of Life, total and by domain:&#xD;
Self Perception: response on 0- to 6-point scale; the range of possible scores is 0 to 30 points.&#xD;
Role-social: response on 0- to 6-point scale; the range of possible scores is 0 to 24 points.&#xD;
Role-emotional: response on 0- to 6-point scale, exactly the same as those used for the Self Perception and Role-social domains.&#xD;
Acne Symptoms:response on 0- to 6-point scale, domain scores range from 0 to 30 points</description>
          <population>per protocol population</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="8.8"/>
                    <measurement group_id="O2" value="12.6" spread="9.1"/>
                    <measurement group_id="O3" value="7.7" spread="7.5"/>
                    <measurement group_id="O4" value="11.5" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Active Treatment Period- 20 weeks Post-treatment Period- 124 weeks</time_frame>
      <desc>All safety analyses were carried out using the safety population, which was defined as all subjects who received at least 1 dose of study treatment. Thus, overall results are depicted for all the subjects</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Treatment Arm</title>
          <description>Absorica capsules 0.5 mg/kg/day for 4 weeks, followed by 1.0 mg/kg/day for 16 weeks.&#xD;
Study ABS1517LT was a Phase 4, open-label, single-arm study in subjects with severe recalcitrant nodular acne, consisting of 2 phases: a 20-week (5-month) Active Treatment Phase and a 104-week (2-year) Post Treatment Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials</name_or_title>
      <organization>SPIL</organization>
      <phone>912266455645</phone>
      <email>Clinical.Trials@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

